NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments
Go back to NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments| (NASDAQ: ELAB) | Delayed: 1.35 -0.04 (2.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.39 | 52 Week High | $ | |||
| Open | $1.38 | 52 Week Low | $ | |||
| Day High | $1.41 | P/E | N/A | |||
| Day Low | $1.34 | EPS | $ | |||
| Volume | 287,208 | |||||
